Deep Tech Startups

Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases. It focuses on innovation in both product and process development to lower cell therapy production costs and expand indication coverage.

1 investor

Neuphonic builds ultra-low latency text-to-speech models for real-time AI voice interactions that run on-device without internet connectivity. The company develops open-source AI voice technology enabling developers to build voice-native applications.

1 investor

Neural Defend provides deepfake detection technology to protect people and organizations against synthetic media fraud. The company serves enterprises and individuals seeking to verify digital authenticity in an increasingly AI-generated content landscape.

1 investor

Neural Dynamics Technologies develops neural interface technology aimed at advancing neuroscience research and treating neurological diseases. The company brings together neuroscientists, engineers, and clinicians in an interdisciplinary approach.

1 investor

Neuralk builds foundational tabular AI models and autonomous agentic workflows that generate predictions (classification, regression, timeseries) on enterprise business data without requiring re-training. Its predictive AI is aimed at enterprises and data professionals across industries handling tabular data.

1 investor

Neural Machine develops technology to connect humans and machines, aiming to create a new form of "human computing" that extends the human mind. The company is built by a team of engineers, scientists, and artists.

1 investor

NeuralTeks develops AI-powered tools for laboratory analysis, specifically targeting microbiology and microbial identification in pharmaceutical, biotechnology, and analytical settings. The platform aims to accelerate analysis speed, improve accuracy, and reduce costs for laboratory operations.

1 investor

Neuramancer is a Bavarian IT-security startup that builds forensic media-analysis software to detect deepfakes and AI manipulation in images and videos, including heavily compressed material from unknown sources. Its tools, offered as SaaS or on-premise with API integration and European hosting, serve fact-checkers, fraud investigators, analysts, and industries such as insurance and media.

1 investor

Neuramatix develops and licenses NeuraBase, a proprietary neural engine that builds memory-efficient adaptive neural networks modeled on biological brain function for tasks such as language translation, bioinformatics, robotic control, speech, and reinforcement learning. The technology is offered for research or commercial licensing across a range of AI and machine learning applications.

1 investor

Neuramill develops AI-based solutions for precision manufacturing, leveraging computer vision and machine learning. The company serves manufacturers and aims to improve production quality and efficiency through physical AI applications.

1 investor

Neuraspace develops AI and machine learning models to predict satellite collisions and manage space debris for satellite operators and space agencies. The company aims to enable safe and automated space operations while maintaining a sustainable orbital environment.

1 investor

Neurescue develops a medical device that treats cardiac arrest patients by inserting a balloon-occlusion device through the femoral artery to increase blood flow to the heart and brain during chest compressions. The device targets patients ineligible for defibrillation and uses automated pressure-limited inflation to improve resuscitation outcomes.

1 investor

NeuroChat is a brain-computer interface platform that lets people with severe motor and speech impairments (cerebral palsy, ALS, stroke, multiple sclerosis, neurotrauma) type text and communicate through mental effort, with built-in online translation between languages. It also serves as a neurotraining system for developing cognitive functions such as attention, memory, and reaction speed by analyzing EEG data via a hardware headset and software interface.</parameter> <parameter name="founders">[{"full_name": "Наталия Галкина", "title": "Генеральный директор (CEO)"}, {"full_name": "Александр Лужин", "title": "Руководитель НИОКР НейроЧат"}, {"full_name": "Алеся Чичинкина", "title": "Директор по коммуникациям и международному развитию"}, {"full_name": "Юрий Мустафин", "title": "Технический директор (CTO)"}, {"full_name": "Александр Каплан", "title": "Научный руководитель проекта"}, {"full_name": "Игорь Зимин", "title": "Директор по развитию бизнеса"}, {"full_name": "Галина Ершова", "title": "Руководитель патронажной службы"}]

1 investor

NeuroEquilibrium operates a network of clinics specializing in diagnosis and treatment of vertigo, dizziness, and balance disorders through a deep-tech platform that integrates cloud technology, computer vision, and remote diagnostics. The company serves patients and healthcare providers in India and globally, aiming to standardize care for vestibular disorders.

1 investor

Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.

1 investor

NeuroGenesis develops cell therapies for neurodegenerative diseases, leveraging its NG CELL platform to enhance stem cells for treating conditions like multiple sclerosis and ALS. The company is advancing Phase IIb clinical trials in Europe and Israel with a focus on remyelinating and regenerative cellular medicine.

1 investor

Neurolieve is a life-science company developing therapeutics for neuropathic and chronic pain, with expertise in neuroscience, clinical pain medicine and drug development. Its lead program, NLV-01, is built on protein-engineering technology contributed by co-founding partner LifeArc.

1 investor

Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.

1 investor

NeurOptics develops pupillometry technologies for clinical decision-making in critical care, neurology, neurosurgery, and emergency medicine. The company serves medical professionals and clinical researchers globally.

1 investor

Neurosity makes the Crown, a wearable brain-computer interface headset that measures brain waves and plays adaptive music to help users increase focus and concentration. It offers an app with dashboards for tracking performance and an SDK for developers to build neuro applications.

1 investor

NeuroSky provides biofeedback and biometric assessment solutions that help companies optimize hiring decisions, identify employee training needs, and improve workforce productivity through data-driven insights on cognitive performance and employee capabilities.

1 investor

Axoneurotech develops neural engineering technology using a biology-first approach at the intersection of biology and engineering.

1 investor

NeuroTx develops AI-powered electroceutical and neurotechnology solutions that use neural decoding and non-invasive vagus nerve stimulation to support sleep quality, cognitive function, and metabolic health. The company integrates wearable devices, mobile applications, and machine learning to deliver personalized bio-signal-based interventions for consumers and patients.

1 investor

Neuroute is an AI-powered platform that accelerates clinical trial execution through patient recruitment, trial monitoring, and predictive analytics. It serves pharmaceutical companies and clinical research organizations conducting clinical trials.

1 investor